KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Raw Materials (2018 - 2025)

Twist Bioscience (TWST) has disclosed Raw Materials for 6 consecutive years, with $30.9 million as the latest value for Q2 2023.

  • On a quarterly basis, Raw Materials changed 0.04% to $30.9 million in Q2 2023 year-over-year; TTM through Jun 2023 was $30.9 million, a 0.04% change, with the full-year FY2022 number at $28.8 million, up 53.3% from a year prior.
  • Raw Materials was $30.9 million for Q2 2023 at Twist Bioscience, down from $33.6 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $33.6 million in Q1 2023 to a low of $3.5 million in Q1 2019.
  • A 5-year average of $21.0 million and a median of $23.8 million in 2021 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: skyrocketed 205.19% in 2021, then dropped 0.04% in 2023.
  • Twist Bioscience's Raw Materials stood at $4.9 million in 2019, then surged by 102.86% to $9.9 million in 2020, then surged by 205.19% to $30.3 million in 2021, then grew by 10.62% to $33.6 million in 2022, then fell by 7.93% to $30.9 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Raw Materials are $30.9 million (Q2 2023), $33.6 million (Q1 2023), and $33.6 million (Q4 2022).